对比增强CT能否可靠识别胰腺导管腺癌:一项基于人群的敏感性与假阴性因素研究
该回顾性人群研究纳入154例胰腺导管腺癌患者的176次对比增强CT,评估其检出敏感性并分析假阴性相关因素。总体敏感性为83.9%,肿瘤≤2 cm、无肝转移及影像学可切除病变时敏感性明显降低;双期胰腺方案敏感性高于单期(88.4% vs 82.1%)。
要点
- 对比增强CT检出胰腺导管腺癌总体敏感性为83.9%,肿瘤≤2 cm时降至45.4%。
- 无肝转移及影像学可切除病变与假阴性结果独立相关(OR分别为4.94和4.13)。
- 作者建议对疑似胰腺疾病患者采用专门的双期胰腺CT方案以提高敏感性。
核心结论
- 对比增强CT检出胰腺导管腺癌的总体敏感性为83.9%,但在小肿瘤(≤2 cm)和影像学可切除病变等情境下明显降低;作者认为应努力最大程度提高对比增强CT的敏感性。
研究设计与样本
- 回顾性研究,通过癌症登记处识别2014至2015年确诊的胰腺导管腺癌患者,共纳入154例患者的176次对比增强CT(单期127次,双期49次)。
诊断标准与关键数值
- 对比增强CT检出胰腺导管腺癌的总体敏感性为125/149(83.9%)。
- 单期方案敏感性为87/106(82.1%),双期方案为38/43(88.4%)。
- 肿瘤≤2 cm敏感性为45.4%,>2 cm为90.6%;无肝转移为78.0%,有肝转移为95.9%;影像学可切除病变为65.3%,不可切除为93.0%。
临床应用与阅片要点
- 临床怀疑胰腺导管腺癌时,单期方案敏感性为82.1%,双期方案为88.4%,作者建议对疑似胰腺疾病患者采用专门的双期胰腺对比增强CT方案。
- 假阴性结果与无肝转移(OR 4.94,95% CI 1.29-22.99)和影像学可切除病变(OR 4.13,95% CI 1.07-16.65)相关。
- 影像申请单有临床怀疑恶性肿瘤时假阴性风险降低(OR 0.24,95% CI 0.07-0.75),肿瘤>2 cm也与假阴性负相关(OR 0.10,95% CI 0.02-0.44)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the sensitivity of contrast-enhanced computed tomography (CECT) in detecting pancreatic ductal adenocarcinoma (PDAC) and identify factors associated with false negatives (FNs).
METHODS: Patients diagnosed with PDAC in 2014-2015 were retrospectively identified by a cancer registry. CECTs performed during the diagnostic interval were retrospectively classified as true positive (TP), indeterminate, or FN. Sensitivity TP/(TP+FN) was calculated for all CECTs and the following subgroups: protocol (uniphasic vs. biphasic); tumor size (≤ 2 cm vs. > 2 cm); and resectability (potentially resectable vs. unresectable). Multivariate logistic regression was performed to assess which of the following factors were associated with FN: clinical suspicion of PDAC; size >2 cm; presence of metastases; protocol; isoattenuating tumor; and potentially resectable disease on imaging.
RESULTS: In total, 176 CECTs (127 uniphasic; 49 biphasic) in 154 patients (90 men, mean age 72 ± 11 years) were included. Sensitivity was 125/149 (83.9%) overall and 87/106 (82.1%) and 38/43 (88.4%) for uniphasic and biphasic protocols, respectively. Sensitivity was decreased for tumors ≤ 2 cm (45.4% vs. 90.6%), no liver metastases (78.0% vs. 95.9%), and potentially resectable disease (65.3% vs. 93.0%). Factors significantly associated with FN were clinical suspicion (OR, 0.24, 95% CI: 0.07-0.75), size>2 cm (OR, 0.10, 95% CI: 0.02-0.44), absence of liver metastases (OR, 4.94, 95% CI: 1.29-22.99), and potentially resectable disease (OR, 4.13, 95% CI: 1.07-16.65).
CONCLUSIONS: In our population, the overall sensitivity of CECT to detect PDAC is 83.9%; however, this is substantially lower in several scenarios, including patients with potentially resectable disease. This finding has important implications for patient outcomes and efforts to maximize CECT sensitivity should be sought.
CLINICAL RELEVANCE STATEMENT: The sensitivity of CECT to detect PDAC is significantly decreased in the setting of sub-2 cm tumors and potentially resectable disease. A dedicated biphasic pancreatic CECT protocol has higher sensitivity and should be applied in patients with suspected pancreatic disease.
KEY POINTS: • The sensitivities of contrast-enhanced CT for the detection of PDAC were 87/106 (82.1%) and 38/43 (88.4%) for uniphasic and biphasic protocols, respectively. • The sensitivity of contrast-enhanced CT was decreased for small tumors ≤ 2 cm (45.4% vs. 90.6%), if there were no liver metastases (78.0% vs. 95.9%), and with potentially resectable disease (65.3% vs. 93.0%). • Absence of liver metastases (OR, 4.94, 95% CI: 1.29-22.99) and potentially resectable disease (OR, 4.13, 95% CI: 1.07-16.65) were associated with a false--negative (FN) CT result; suspicion of malignancy on the imaging requisition (OR, 0.24, 95% CI: 0.07-0.75) and size > 2 cm (OR, 0.10, 95% CI: 0.02-0.44) were negatively associated with FN.
引用
- LeBlanc, Kang, Costa, et al. Can we rely on contrast-enhanced CT to identify pancreatic ductal adenocarcinoma? A population-based study in sensitivity and factors associated with false negatives. Eur Radiol. 2023. PMID: 37266655. doi:10.1007/s00330-023-09758-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。